Table 1 Anthropometric data, biochemistry, fractures and agents that affect bone metabolism for patients treated with teriparatide at the start of the treatment, for all women (n = 40) and for all women with 10 years follow-up (n = 20). The p-value shows comparison between study start and 10 years’ follow-up in the 20 women who fulfilled the entire teriparatide study
From: Teriparatide treatment in severe osteoporosis – a controlled 10-year follow-up study
Anthropometric and treatment data Mean (Standard Deviation) | Teriparatide at treatment start n = 40 | Teriparatide at treatment start n = 20 | Teriparatide 10 years after treatment start n = 20 | p-value 10 years versus start n = 20 |
|---|---|---|---|---|
Age (years) | 69.5 (10.9) | 64.2 (12.3) | 74.7 (12.5) | < 0.001 |
Height (m) | 1.59 (0.86) | 1.60 (0.91) | 1.58 (0.11) | 0.003 |
Body weight (kg) | 60.3 (10.2) | 61.6 (11.7) | 60.8 (16.2) | 0.62 |
BMI (kg/m2) | 24.0 (3.7) | 23.7 (4.1) | 24.3 (5.0) | 0.25 |
Waist (cm) | 86.8 (10.5) | 86.7 (9.3) | 90.6 (14.7) | 0.14 |
Hip (cm) | 101.5 (7.6) | 102.2 (9.5) | 100.6 (13.5) | 0.55 |
Waist to hip ratio | 0.86 (0.09) | 0.87 (0.07) | 0.91 (0.10) | 0.51 |
BMD femoral neck (g/cm2) | 0.68 (0.15) | 0.68 (0.17) | 0.69 (0.20) | 0.97 |
BMD lumbar spine(g/cm2) | 0.89 (0.20) | 0.88 (0.22) | 0.93 (0.25) | 0.62 |
T-score femoral neck | −2.60 (1.16) | −2.58 (1.30) | −2.59 (1.63) | 0.62 |
T-score lumbar spine | −2.61 (1.69) | −2.60 (1.82) | − 2.25 (2.09) | 0.39 |
S-Osteocalcin (μg/L) | 12.8 (6.3) | 14.9 (6.8) | 21.6 (26.0) | 0.55 |
S-Ca total (mmol/L) | 2.32 (0.09) | 2.29 (0.06) | 2.37 (0.11) | 0.02 |
S-Ca ion (mmol/L) | 1.23 (0.07) | 1.20 (0.08) | 1.25 (0.04) | 0.26 |
S-PTH (pmol/L) | 4.3 (1.0) | 4.1 (0.7) | 3.8 (1.4) | 0.13 |
Subjects with fractures, n (%) | 40 (100%) | 20 (100%) | 7 (35.0%) | < 0.001 |
Cortisone treatment, n (%) | 10 (25.0%) | 4 (20.0%) | 4 (20.0%) | 1.00 |
Estrogen replacement, n (%) | 8 (20.0%) | 4 (20.0%) | 2 (10.0%) | 0.66 |
Bone specific agent, n (%) | 23 (57.5%) | 13 (65.0%) | 16 (80.0%) | 0.48 |